← All trials
NCT05128786
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2021
- Primary completion
- Aug 12, 2022
- Completion date
- Jul 15, 2023
- First posted
- Nov 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai PerHum Therapeutics Co., Ltd.Lead sponsor
- Fudan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.